<?xml version='1.0' encoding='utf-8'?>
<document id="22624502"><sentence text="Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study."><entity charOffset="19-28" id="DDI-PubMed.22624502.s1.e0" text="ritonavir" /><entity charOffset="32-42" id="DDI-PubMed.22624502.s1.e1" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s1.e0" e2="DDI-PubMed.22624502.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s1.e0" e2="DDI-PubMed.22624502.s1.e1" /></sentence><sentence text="Danoprevir, a potent, selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease, is metabolized by cytochrome P450 (CYP) 3A"><entity charOffset="0-10" id="DDI-PubMed.22624502.s2.e0" text="Danoprevir" /></sentence><sentence text=" Clinical studies in HCV patients have shown a potential need for a high danoprevir daily dose and/or dosing frequency" /><sentence text=" Ritonavir, an HIV-1 protease inhibitor (PI) and potent CYP3A inhibitor, is used as a pharmacokinetic enhancer at subtherapeutic doses in combination with other HIV PIs"><entity charOffset="1-10" id="DDI-PubMed.22624502.s4.e0" text="Ritonavir" /></sentence><sentence text=" Coadministering danoprevir with ritonavir as a pharmacokinetic enhancer could allow reduced danoprevir doses and/or dosing frequency"><entity charOffset="17-27" id="DDI-PubMed.22624502.s5.e0" text="danoprevir" /><entity charOffset="33-42" id="DDI-PubMed.22624502.s5.e1" text="ritonavir" /><entity charOffset="93-103" id="DDI-PubMed.22624502.s5.e2" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s5.e0" e2="DDI-PubMed.22624502.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s5.e0" e2="DDI-PubMed.22624502.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22624502.s5.e0" e2="DDI-PubMed.22624502.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22624502.s5.e1" e2="DDI-PubMed.22624502.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22624502.s5.e1" e2="DDI-PubMed.22624502.s5.e2" /></sentence><sentence text=" Here we evaluate the impact of ritonavir on danoprevir pharmacokinetics"><entity charOffset="32-41" id="DDI-PubMed.22624502.s6.e0" text="ritonavir" /><entity charOffset="45-55" id="DDI-PubMed.22624502.s6.e1" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s6.e0" e2="DDI-PubMed.22624502.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s6.e0" e2="DDI-PubMed.22624502.s6.e1" /></sentence><sentence text="" /><sentence text="The effects of low-dose ritonavir on danoprevir pharmacokinetics were simulated using Simcyp, a population-based simulator"><entity charOffset="24-33" id="DDI-PubMed.22624502.s8.e0" text="ritonavir" /><entity charOffset="37-47" id="DDI-PubMed.22624502.s8.e1" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s8.e0" e2="DDI-PubMed.22624502.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s8.e0" e2="DDI-PubMed.22624502.s8.e1" /></sentence><sentence text=" Following results from this drug-drug interaction (DDI) model, a crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics"><entity charOffset="184-193" id="DDI-PubMed.22624502.s9.e0" text="ritonavir" /><entity charOffset="197-207" id="DDI-PubMed.22624502.s9.e1" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s9.e0" e2="DDI-PubMed.22624502.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s9.e0" e2="DDI-PubMed.22624502.s9.e1" /></sentence><sentence text=" Volunteers received a single oral dose of danoprevir 100 mg in a fixed sequence as follows: alone, and on the first day and the last day of 10-day dosing with ritonavir 100 mg every 12 hours"><entity charOffset="43-53" id="DDI-PubMed.22624502.s10.e0" text="danoprevir" /><entity charOffset="160-169" id="DDI-PubMed.22624502.s10.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22624502.s10.e0" e2="DDI-PubMed.22624502.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s10.e0" e2="DDI-PubMed.22624502.s10.e1" /></sentence><sentence text="" /><sentence text="The initial DDI model predicted that following multiple dosing of ritonavir 100 mg every 12 hours for 10 days, the danoprevir area under the plasma concentration-time curve (AUC) from time zero to 24 hours and maximum plasma drug concentration (C(max)) would increase by about 3"><entity charOffset="66-75" id="DDI-PubMed.22624502.s12.e0" text="ritonavir" /><entity charOffset="115-125" id="DDI-PubMed.22624502.s12.e1" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s12.e0" e2="DDI-PubMed.22624502.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s12.e0" e2="DDI-PubMed.22624502.s12.e1" /></sentence><sentence text="9- and 3" /><sentence text="2-fold, respectively" /><sentence text=" The clinical results at day 10 of ritonavir dosing showed that the plasma drug concentration at 12 hours postdose, AUC from time zero to infinity and C(max) of danoprevir increased by approximately 42-fold, 5"><entity charOffset="35-44" id="DDI-PubMed.22624502.s15.e0" text="ritonavir" /></sentence><sentence text="5-fold and 3" /><sentence text="2-fold, respectively, compared with danoprevir alone"><entity charOffset="36-46" id="DDI-PubMed.22624502.s17.e0" text="danoprevir" /></sentence><sentence text=" The DDI model was refined with the clinical data and sensitivity analyses were performed to better understand factors impacting the ritonavir-danoprevir interaction"><entity charOffset="133-142" id="DDI-PubMed.22624502.s18.e0" text="ritonavir" /></sentence><sentence text="" /><sentence text="DDI model simulations predicted that danoprevir exposures could be successfully enhanced with ritonavir coadministration, and that a clinical study confirming this result was warranted"><entity charOffset="37-47" id="DDI-PubMed.22624502.s20.e0" text="danoprevir" /><entity charOffset="94-103" id="DDI-PubMed.22624502.s20.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22624502.s20.e0" e2="DDI-PubMed.22624502.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s20.e0" e2="DDI-PubMed.22624502.s20.e1" /></sentence><sentence text=" The clinical results demonstrate that low-dose ritonavir enhances the pharmacokinetic profile of low-dose danoprevir such that overall danoprevir exposures can be reduced while sustaining danoprevir trough concentrations"><entity charOffset="48-57" id="DDI-PubMed.22624502.s21.e0" text="ritonavir" /><entity charOffset="107-117" id="DDI-PubMed.22624502.s21.e1" text="danoprevir" /><entity charOffset="136-146" id="DDI-PubMed.22624502.s21.e2" text="danoprevir" /><entity charOffset="189-199" id="DDI-PubMed.22624502.s21.e3" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e0" e2="DDI-PubMed.22624502.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e0" e2="DDI-PubMed.22624502.s21.e1" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e0" e2="DDI-PubMed.22624502.s21.e2" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e0" e2="DDI-PubMed.22624502.s21.e3" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e1" e2="DDI-PubMed.22624502.s21.e1" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e1" e2="DDI-PubMed.22624502.s21.e2" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e1" e2="DDI-PubMed.22624502.s21.e3" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e2" e2="DDI-PubMed.22624502.s21.e2" /><pair ddi="false" e1="DDI-PubMed.22624502.s21.e2" e2="DDI-PubMed.22624502.s21.e3" /></sentence><sentence text="" /></document>